BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 8568811)

  • 21. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
    Caplin BE; Ohya Y; Marshall MS
    J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
    Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
    J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
    J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract]   [Full Text] [Related]  

  • 24. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J; Kung HF; Manne V
    Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
    Qian Y; Blaskovich MA; Saleem M; Seong CM; Wathen SP; Hamilton AD; Sebti SM
    J Biol Chem; 1994 Apr; 269(17):12410-3. PubMed ID: 8175645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
    Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
    Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I.
    Carrico D; Blaskovich MA; Bucher CJ; Sebti SM; Hamilton AD
    Bioorg Med Chem; 2005 Feb; 13(3):677-88. PubMed ID: 15653335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R; Mohan RR; Ahmad N; Mukhtar H
    Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
    Qian Y; Marugan JJ; Fossum RD; Vogt A; Sebti SM; Hamilton AD
    Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
    Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
    J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
    Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
    Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase.
    Wang GT; Wang X; Wang W; Hasvold LA; Sullivan G; Hutchins CW; O'Conner S; Gentiles R; Sowin T; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):153-8. PubMed ID: 15582430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
    deSolms SJ; Giuliani EA; Graham SL; Koblan KS; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Scholz TH; Wiscount CM; Gibbs JB; Smith RL
    J Med Chem; 1998 Jul; 41(14):2651-6. PubMed ID: 9651171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 39. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NMR studies of novel inhibitors bound to farnesyl-protein transferase.
    Koblan KS; Culberson JC; Desolms SJ; Giuliani EA; Mosser SD; Omer CA; Pitzenberger SM; Bogusky MJ
    Protein Sci; 1995 Apr; 4(4):681-8. PubMed ID: 7613466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.